Dinaciclib
- Generic Name
- Dinaciclib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H28N6O2
- CAS Number
- 779353-01-4
- Unique Ingredient Identifier
- 4V8ECV0NBQ
- Background
Dinaciclib has been used in trials studying the treatment of rrMM, rrCLL, rrDLBCL, Solid Tumors, and Solid Neoplasm, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-03-31
- Last Posted Date
- 2014-06-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 16
- Registration Number
- NCT01096342
- Locations
- ๐บ๐ธ
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
๐ธ๐ฌNational University Hospital, Singapore, Singapore
๐บ๐ธWayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
Dinaciclib in Treating Patients With Stage III-IV Melanoma
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT01026324
- Locations
- ๐บ๐ธ
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Dinaciclib in Treating Patients With Stage IV Melanoma
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 72
- Registration Number
- NCT00937937
- Locations
- ๐บ๐ธ
Cancer Center of Kansas - Chanute, Chanute, Kansas, United States
๐บ๐ธSpringfield Memorial Hospital, Springfield, Illinois, United States
๐บ๐ธLogan Health Medical Center, Kalispell, Montana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2024. All Rights Reserved by MedPath